SEARCH

SEARCH BY CITATION

References

  • Addiego, J., Kasper, C., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B., Aledort, L. (1993) Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet, 342, 462464.
  • Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., White, G., Lee, M. (1994) A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 83, 24282435.
  • Briët, E., Rosendal, R., Kreuz, W., Rasi, V., Peerlink, K., Vermylen, J., Ljung, R., Rocino, A., Addiego, J., Lorenzo, J.I., Pabinger, I. (1994) High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thrombosis and Haemostasis, 72, 162164.
  • De Biasi, R., Rocino, A., Papa, M.L., Salerno, E., Mastrullo, L., De Blasi, D. (1994) Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thrombosis and Haemostasis, 71, 544547.
  • Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Güngör, T., Krackhardt, B., Kornhuber, B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594598.
  • Ewing, N.P. & Kasper, C.K. (1982) In vitro detection of mild inhibitors to factor VIII in haemophilia. American Journal of Clinical Pathology, 77, 749752.
  • Gilles, J.G.G., Jacquemin, M.G., Saint-Remy, J.M.R. (1997) Factor VIII inhibitors. Thrombosis and Haemostasis, 78, 641646.
  • Guérois, C., Laurian, Y., Rothschild, C., Parquet-Gernez, A., Duclos, A.M., Négrier, C., Vicariot, M., Fimbel, B., Fressinaud, E., Fiks-Sigaud, M., Derlon, A., Berthier, A.M., Gaillard, S., Bertrand, M.A. (1995) Incidence of factor VIII inhibitor development in severe hemophilia A patients treated with one brand of highly purified plasma-derived concentrate. Thrombosis and Haemostasis, 73, 215218.
  • Hoyer, L.W. (1995) Why do so many haemophilia A patients develop an inhibitor? British Journal of Haematology, 90, 498501.
  • Jorquera, J.I., Carmona, E., Aznar, J.A., Peiró, A., Sánchez-Cuenca, J.M. (1985) A standardized method for measuring anti-F VIII: C inhibitors in haemophilia A by coagulation inhibition in agarose gel. Thrombosis and Haemostasis, 54, 377380.
  • Kasper, C.K., Aledort, L.M., Counts, R.B., Edson, J.R., Fratantoni, J.C., Green, D., Hampton, J.W., Hiltgartner, M.W., Lazerson, J., Levine, P.H., McMillan, C.W., Pool, J.G., Shapiro, S.S., Shulman, N.R., Van Eys, J.A. (1975) A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica, 34, 869872.
  • Kavakli, K., Gringeri, A., Bader, R., Nisli, G., Polat, A., Aydinok, Y. (1998) Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia, 4, 104108.
  • Kreuz, W., Escuriolaettingshausen, C., Martinezsaguer, I., Güngör, T., Kornhuber, B. (1996) Epidemiology of inhibitors in haemophilia A. Vox Sanguinis, 70, 28.
  • Lusher, J.M., Arkin, S., Abildgaard, C.F., Schwartz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine, 328, 453459.
  • Penner, J.A. (1999) Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate Autoplex T. Haemophilia, 5, 19.
  • Rothschild, C., Laurian, Y., Satre, E.P., Borel Derlon, A., Chambost, H., Moreau, P., Goudemand, J., Parquet, A., Peynet, J., Vicariot, M., Beurrier, P., Claeyssens, S., Durin, A., Faradji, A., Fressinaud, E., Gaillard, S., Guérin, V., Guérois, C., Pernod, G., Pouzol, P., Schved, J.F., Gazengel, C. (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis, 80, 779783.
  • Scharrer, I. & Neutzling, O. (1993) Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagulation and Fibrinolysis, 4, 753758.
  • Scharrer, I., Neutzling, O., Schwaab, R., Oldenburg, J., Ehrlich, H. (1998) Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Annals of Hematology, 76, A1A6.
  • Scharrer, I., Bray, G.L., Neutzling, O. (1999) Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia, 5, 145154.
  • Schwaab, R., Brackmann, H.H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E.G.D., Oldenburg, J. (1995) Haemophilia A: mutation type determines risk of inhibitor formation. Thrombosis and Haemostasis, 74, 14021406.